The deal will allow Cubist to obtain Entereg, an oral, peripherally acting mu opioid receptor antagonist. The drug is the only FDA-approved treatment for speeding upper and lower gastrointestinal recovery time following partial large or small bowel resection surgery with primary anastomosis.
Related Articles on Pain Management:
Adaptation to Upright Walking Leaves Humans Susceptible to Backbone Fractures, Pain
Researchers to Study ‘Scrambler Therapy’ for Pain Relief
Chronic Pain Care for Women Cost $12.9 Billion in 2008
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.